Form 4: CRISPR Therapeutics CFO Sells Shares to Cover Tax Obligations After RSU Vesting

Chief Financial Officer of CRISPR Therapeutics, Raju Prasad, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics, reported changes in beneficial ownership of company stock.
• On March 20, 2025, 6,250 restricted stock units (RSUs) vested, representing a contingent right to receive one share of CRSP Common Shares per unit.
• Following the vesting, Mr. Prasad sold 2,197 shares on March 21, 2025, at a price of $41.23 per share to cover tax withholding obligations.
• After these transactions, Mr. Prasad directly owns 16,767 common shares and 18,750 restricted stock units.
• The sale was mandated by the company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often related to compensation packages and tax obligations. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• Selling shares to cover tax obligations upon vesting is a standard practice among executives.
• The amount of shares sold for tax purposes is proportional to the executive's tax bracket and the value of the vested shares.
• Comparable companies such as Editas Medicine and Intellia Therapeutics also have executives who regularly report similar transactions.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price in the short term.
• The transaction does not significantly affect the company's operations or financial condition.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Raju Prasad, Chief Financial Officer, Form 4, Beneficial Ownership, Restricted Stock Units, Tax Withholding, Share Sale